ArticleCancer cell2024
Interruption of the intratumor CD8
Abstract read
In one paragraph
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers.
0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
84 citing papers in PubMed.
- Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer.Journal for immunotherapy of cancer · 2025Trial
- Trial
- The current role of immunotherapy in treating nasopharyngeal carcinoma.Human vaccines & immunotherapeutics · 2026Review
- AIM2 in tregs restrains anti-PD-1 efficacy by reinforcing immune suppression in MC38 colorectal cancer.iScience · 2026Article
- Impact of periodontitis on the efficacy of neoadjuvant immunochemotherapy in non-small cell lung cancer: a multi-center real-world study.International journal of clinical oncology · 2026Article
- Molecular heterogeneity and clonal origin of CCR8Nature communications · 2026Article
- Mathematical and Mouse Models Identify Regulatory T Cell Influx as A Key Determinant of Acquired Resistance to PD-1 Immunotherapy.Cancer research · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Loss of NCCRP1 overcomes immune evasion in lung adenocarcinoma.Journal for immunotherapy of cancer · 2026Article
- ISPAT-3D: Spatially Varying Conditional Volumetric Network Estimation for 3D Tumor Imaging.Research square · 2026Article
- Immune checkpoint B7x promotes immune evasion and resistance to PD-1/PD-L1 blockade in bladder cancer.Genes & diseases · 2026Article
- Nicotinamide mononucleotide enhances anti-tumor effect by resetting macrophages toward the inflammatory M1-like phenotype.Molecular therapy. Oncology · 2026Article
- Regulatory T cells in cancer and inflammation.Signal transduction and targeted therapy · 2026Review
- LncRNA SOX21-AS1 is associated with poor prognosis and immunomodulation in glioblastoma.Translational cancer research · 2026Article
- CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma.bioRxiv : the preprint server for biology · 2026Article
- Establishment of prognostic prediction model based on lipid metabolism related genes in esophageal squamous cell carcinoma by machine learning algorithms.BMC gastroenterology · 2026Article
- Biomaterials for biomarker imaging and detection.Journal of advanced research · 2026Review
- Aging-Driven Immunosuppression: The Role of Tregs in the Ovarian Tumor Microenvironment.Aging cell · 2026Article
- Enhancing antitumour nanovaccine efficacy via integrated cholesterol modulation in situ.Nature nanotechnology · 2026Article
- ISPAT-3D: Spatially Varying Conditional Volumetric Network Estimation for 3D Tumor Imaging.bioRxiv : the preprint server for biology · 2026Article
24 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
17 authors.
Shannon N GeelsInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Alexander MoshenskyInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Rachel S SousaInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Center for Complex Biological Systems, University of California, Irvine, Irvine, CA, USA; NSF-Simons Center for Multiscale Cell Fate Research, University of California, Irvine, Irvine, CA, USA.
Claire MuratInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Matias A BustosDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, CA, USA.
Benjamin L WalkerCenter for Complex Biological Systems, University of California, Irvine, Irvine, CA, USA; NSF-Simons Center for Multiscale Cell Fate Research, University of California, Irvine, Irvine, CA, USA.
Rima SinghInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Biological Chemistry, University of California, Irvine, Irvine, CA, USA.
Stacey N HarbourDepartment of Pathology, University of Alabama, Birmingham, Birmingham, AL, USA.
Giselle GutierrezInstitute for Immunology, University of California, Irvine, Irvine, CA, USA.
Michael HwangInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Thorsten R MempelMassachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Casey T WeaverDepartment of Pathology, University of Alabama, Birmingham, Birmingham, AL, USA.
Qing NieCenter for Complex Biological Systems, University of California, Irvine, Irvine, CA, USA; NSF-Simons Center for Multiscale Cell Fate Research, University of California, Irvine, Irvine, CA, USA; Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA, USA.
Dave S B HoonDepartment of Translational Molecular Medicine, Saint John's Cancer Institute, Santa Monica, CA, USA.
Anand K GanesanDepartment of Dermatology, University of California, Irvine, Irvine, CA, USA.
Shivashankar OthyInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA.
Francesco MarangoniInstitute for Immunology, University of California, Irvine, Irvine, CA, USA; Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA, USA. Electronic address: f.marangoni@uci.edu.
Funding
Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9MStrategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI PAI, SARA ISABEL · 2019 to 2023
$8.4MUCI P30 Skin Center Systems Biology CoreP30AR075047 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI ANDERSEN, BOGI, GANESAN, ANAND K · 2019 to 2025
$5.1MCellular mechanisms by which exhausted T cell responses are restoredR01AI123349 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Thorsten Roman Mempel · 2017 to 2026
$4.5MTissue-Specific Mechanisms of Regulatory T Cells in the CNS during Autoimmune EncephalomyelitisR01AI168063 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Shivashankar Othy · 2022 to 2026
$2.5MNovel macrophage and regulatory T cell interactions that promote the pathogenesis of Duchenne muscular dystrophyR01NS120060 · NINDS · UNIVERSITY OF CALIFORNIA-IRVINE · PI VILLALTA, SERGIO ARMANDO · 2020 to 2024
$2.5MA mechanism to minimize auto-reactivity in the tissue-resident memory T cell poolR01AI163223 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MEMPEL, THORSTEN ROMAN · 2021 to 2025
$2.4MDefining molecular mechanisms of combination adjuvants: a systems immunology, transcriptomics and imaging approachU01AI160397 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI DAVIES, DAVID HUW · 2021 to 2024
$2.4MCue-101 and TCR-T cell Combinatorial Strategy for HPV+ Head and Neck CancersR01CA278212 · NCI · YALE UNIVERSITY · PI Sara Isabel Pai · 2024 to 2026
$2.0MInterdisciplinary Training Program in Skin BiologyT32AR080622 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI Bogi Andersen, Anand K Ganesan · 2022 to 2026
$909kImmunology Research Training GrantT32AI177324 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Eric Pearlman · 2023 to 2026
$735kDisentangling the Epidermal Immune Crosstalk in Inflammatory Skin DiseaseF31AR083279 · NIAMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI MOSHENSKY, ALEXANDER · 2023 to 2025
$136kNCI NIH HHS P01 CA240239NCI NIH HHS P30 CA062203NCI NIH HHS R01 CA278212NIAID NIH HHS R01 AI123349NIAID NIH HHS R01 AI163223NIAID NIH HHS R01 AI168063NIAID NIH HHS T32 AI177324NIAID NIH HHS U01 AI160397NIAMS NIH HHS F31 AR083279NIAMS NIH HHS P30 AR075047NIAMS NIH HHS T32 AR080622NINDS NIH HHS R01 NS120060
Abstract
PD-1 blockade unleashes potent antitumor activity in CD8
Indexed as
CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsImmunotherapyInducible T-Cell Co-Stimulator ProteinInterleukin-2MelanomaProgrammed Cell Death 1 ReceptorT-Lymphocytes, RegulatoryAnimalsCell Line, TumorHumansMelanoma, ExperimentalMiceMice, Inbred C57BLSignal TransductionICOS protein, humanImmune Checkpoint InhibitorsInducible T-Cell Co-Stimulator ProteinInterleukin-2PDCD1 protein, humanProgrammed Cell Death 1 ReceptorCD8(+) T cellsF-IVMfunctional intravital microscopyICOSIL-2melanomaPD-1TregT regulatory cellstumor tolerance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.